Please login to the form below

Not currently logged in
Email:
Password:

Anoro

This page shows the latest Anoro news and features for those working in and with pharma, biotech and healthcare.

AZ prepares to file COPD triple, taking on rival GSK

AZ prepares to file COPD triple, taking on rival GSK

pitted it against GSK’s two-drug LAMA/LABA Anoro (umeclidinium/vilanterol). ... Trelegy hasn’t been growing particularly quickly since its approval a year ago in the US, with £37m ($48m) in revenues in the first six months of the year, while Anoro

Latest news

  • AZ rival to GSK’s COPD drug Anoro fails head-to-head test AZ rival to GSK’s COPD drug Anoro fails head-to-head test

    AZ rival to GSK’ s COPD drug Anoro fails head-to-head test. ... Bevespi demonstrated non-inferiority to GSK’s Anoro (umeclidinium/vilanterol) on peak forced expiratory volume in one second (FEV1) but did not demonstrate superiority on peak FEV1 or non

  • GSK gets maintenance indication for Trelegy GSK gets maintenance indication for Trelegy

    GSK claims Trelegy has made the strongest start of any of GSK’s new Ellipta range of respiratory meds, which also includes Relvar/Breo (fluticasone furoate/vilanterol) and Anoro (vilanterol/umeclidinium

  • EMA approves GSK’s triple COPD therapy EMA approves GSK’s triple COPD therapy

    GSK has been bringing other new COPD therapies to market - including Advair successor Breo/Relvar (fluticasone furoate and vilanterol) and Anoro (umeclidinium bromide and vilanterol) - but with greater competition in the

  • GSK files first application for triple COPD therapy GSK files first application for triple COPD therapy

    protect its franchise with the launch of new two-drug combinations such as Relvar/Breo (vilanterol/fluticasone furoate) and Anoro (vilanterol/umeclidinium bromide).

  • GSK's Bexsero vaccine growing fast, despite GSK's Bexsero vaccine growing fast, despite "tight" supply

    The product continued to slide, but newer drugs such as Anoro (vilanterol/umeclidinium bromide), Breo (vilanterol/fluticasone furoate) and new severe asthma therapy Nucala (mepolizumab) more than offset the decline, with

More from news
Approximately 12 fully matching, plus 40 partially matching documents found.

Latest appointments

  • Theravance hires BMS veteran Pasqualone Theravance hires BMS veteran Pasqualone

    Pasqualone joins Theravance as the company at a crucial time as its development deals with GlaxoSmithKline bears fruit with US approval of respiratory treatment Anoro Ellipta.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics